Skip to Content

Drug Interactions between imiglucerase and miglustat

This report displays the potential drug interactions for the following 2 drugs:

  • imiglucerase
  • miglustat

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

imiglucerase miglustat

Applies to: imiglucerase and miglustat

GENERALLY AVOID: Coadministration with miglustat may increase the clearance of imiglucerase. The mechanism of interaction has not been described. In patients stabilized on imiglucerase 7.5 or 15 units/kg/day, coadministration with miglustat 100 mg orally three times a day for one month appeared to increase the clearance of imiglucerase by 70%, although the results are not conclusive due to the small number of subjects studied and the variable doses of imiglucerase administered. Imiglucerase had no significant effect on the pharmacokinetics of miglustat.

MANAGEMENT: Miglustat labeling states that use with imiglucerase is not indicated.

References

  1. "Product Information. Zavesca (miglustat)." Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.

Switch to consumer interaction data

Drug and food interactions

No interactions were found. This does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Agents for gaucher disease

Therapeutic duplication

The recommended maximum number of medicines in the 'agents for Gaucher disease' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'agents for Gaucher disease' category:

  • imiglucerase
  • miglustat

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.